CBA2029—The Vitality CBA

Below is a placeholder video, until we prepare a unique video introduction for CBA2029.

Summary:

CBA2029 exists to test, operationalize, and validate hypotheses about human health and longevity introduced in FE1997 through FE2029 Those thirteen essays provide initial frameworks—seasonal environmental signaling, maturation as the fulfillment of biological capacity distinct from aging, and longevity as the preservation of adaptive biological architecture—but they are not treated as exhaustive. CBA2029 translates these and related ideas into structured research programs using modern diagnostics, longitudinal health data, and controlled intervention studies. Member companies investigate maturation trajectories, biological resilience, and functional capacity across time, while remaining open to additional mechanisms, models, and evidence relevant to health and longevity. Outcomes are not presumed; they are measured and published through whitepapers and aligned research outputs. The CBA uses a Value-Linked Currency to reward verified improvements in resilience, capacity, and reduced reliance on late-stage medical intervention.

Companies likely to emerge here include:

• Longitudinal Health & Resilience Research Firms
  Organizations conducting multi-year cohort studies that track biomarkers, functional capacity, maturation trajectories, and recovery dynamics across different populations and conditions.

• Metabolic & Seasonal Biology Research Labs
  Firms focused on investigating metabolic flexibility, fuel utilization, and physiological responses to seasonal or cyclical environmental inputs, without presuming dietary conclusions in advance.

• Hormesis & Stress–Recovery Analytics Companies
  Research groups developing methods to quantify stress exposure, recovery timing, adaptive thresholds, and resilience markers—distinguishing beneficial hormetic signals from maladaptive overload.

• Maturation & Functional Capacity Measurement Platforms
  Companies building new measurement frameworks for biological capacity, strength coordination, mobility, cognition, and systemic integration that are not reducible to chronological age.

• Integrative Diagnostics & Time-Series Health Data Firms
  Organizations specializing in longitudinal diagnostics—combining blood markers, imaging, functional testing, wearable data, and environmental inputs into interpretable health trajectories.

• Translational Health Science Companies (Post-Validation)
  Only after sufficient evidence is established, some firms may translate validated findings into clinical protocols, public-health tools, or preventive systems—often migrating to other CBAs at that stage.

Potential migration:

• LPCBA (CBA1618)
  Validated findings related to long-term resilience, systemic health preservation, and population-level robustness may migrate into life-preservation and existential-risk frameworks.
• Insurance, Risk & Actuarial CBAs
  Maturation and resilience metrics may replace age-based assumptions in underwriting, disability modeling, and long-term risk assessment.
• Municipal & Community Health CBAs
  Evidence-based findings may inform non-medical public health strategies, infrastructure planning, and environmental design without lifestyle prescription

IMD Notes

1. Text of IMD note 1.
2. Text of IMD note 2.
3. [EP-4] Text of EP note 4.